Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV20-0251 Monotherapy and Combination with Pembrolizumab in Advanced Solid Tumors
NCT05669430Phase 2Recruiting
- Sponsor
- GV20 Therapeutics
- Start
- Mar 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label trial of GV20-0251 in solid tumor (advanced stage), endometrial carcinoma, head and neck squamous cell carcinoma (HNSCC) and 3 more (4 arms), sponsored by GV20 Therapeutics. Primary endpoints: Objective Response Rate at 12 months and Percentage of Participants With Adverse Events at 12 months. Started Mar 2023; status: recruiting.
02
Drugs
GV20-0251
03
Conditions
solid tumor (advanced stage)endometrial carcinomahead and neck squamous cell carcinoma (HNSCC)cutaneous melanoma (CM)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05669430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669430.